Raleigh pharma's stock hits record high amid drug launch
Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August following regulator approval. The Food and Drug Administration in June approved Verona's lead product, Ohtuvayre, as a maintenance treatment for chronic obstructive pulmonary disease, or COPD, in adult patients.
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...
Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
In June, the Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine), the company's lead candidate. Verona’s stock has surged 36.8% YTD, outperforming the broader market's gain.
Hosted on MSN3mon
Verona (VRNA) Stock Surges 36% in the Past Month: Here's WhyShares of Verona Pharma VRNA have soared 36.3% since the past month, all thanks to the FDA’s approval of its lead pipeline drug in chronic obstructive pulmonary disease (COPD) indication.
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback